CTNI-37. EFFICACY OF ONC201 IN PATIENTS WITH ONC201 FOR RECURRENT H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA

H3 K27M-mutant diffuse midline gliomas (DMG) have a dismal prognosis. We report an integrated analysis for ONC201, a DRD2 antagonist and ClpP agonist, in patients with recurrent H3 K27M DMG administered as monotherapy in 3 clinical studies (NCT03295396, n=20; NCT02525692, n=6; or expanded access, n=...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Neuro Oncol
Hlavní autoři: Arrillaga-Romany, Isabel, Kurz, Sylvia, Tarapore, Rohinton S, Sumrall, Ashley, Butowski, Nicholas, Harrison, Rebecca, de Groot, John, Chi, Andrew, Shonka, Nicole, Umemura, Yoshie, Odia, Yazmin, Mehta, Minesh, Nghiemphu, Phioanh, Cloughesy, Timothy, Taylor, Lynne, Graber, Jerome, Kilburn, Lindsay, Dixit, Karan, Lu, Guangrong, Allen, Joshua, Batchelor, Tracy, Lassman, Andrew, Wen, Patrick
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2020
Témata:
Clinical Trials: Non-Immunologic
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651099/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.204
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky